Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit

This article examines clinical trials utilizing Anti-T Lymphocyte Immunoglobulin for Human Use, Rabbit, a medication commonly known as anti-thymocyte globulin (ATG). These trials investigate its use in various contexts, including stem cell transplantation for blood cancers, prevention of graft-versus-host disease, treatment of systemic sclerosis, and prevention of kidney transplant rejection. The studies aim to optimize dosing, compare effectiveness to other treatments, and evaluate safety profiles in different patient populations.

What is ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT?
How it Works
Uses and Indications
How it is Administered
Potential Side Effects
Ongoing Research

What is ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT?

ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT is a medication used in transplant medicine. It is also known by other names such as rabbit anti-thymocyte globulin (rATG), Thymoglobuline, or Grafalon^[1]. This medication is derived from rabbits that have been immunized with human T cells^[1].

How it Works

This medication works by targeting and reducing the number of T lymphocytes in the body. T lymphocytes are a type of white blood cell that plays a crucial role in the immune system. By reducing these cells, the medication helps to suppress the immune system, which is necessary in transplant patients to prevent rejection of the new organ^[1].

Uses and Indications

ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT is primarily used in the following situations:

Prevention of organ rejection in transplant patients, particularly in kidney transplants^[2]
Treatment of acute graft-versus-host disease (GVHD) in patients who have received stem cell transplants^[3]
As part of conditioning regimens before stem cell transplantation for various blood cancers like acute myeloid leukemia (AML)^[4]
Treatment of certain autoimmune diseases, such as severe aplastic anemia^[5]

How it is Administered

This medication is typically given through intravenous (IV) infusion. The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient. For example:

In kidney transplant patients, it may be given as a dose of 1.5 mg/kg per day for 3-5 days^[2]
In stem cell transplant conditioning regimens, doses may range from 2.5 mg/kg to 10 mg/kg total, given over 2-4 days^[1]

It’s important to note that this medication should only be administered under the close supervision of healthcare professionals experienced in transplant medicine.

Potential Side Effects

As with any powerful immunosuppressant, ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT can have significant side effects. Some potential side effects include:

Increased risk of infections
Fever and chills
Allergic reactions
Low blood cell counts
Nausea and vomiting
Headache
Diarrhea

Patients receiving this medication will be closely monitored for these and other potential side effects^[2].

Ongoing Research

Several clinical trials are currently investigating the use of ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT in various contexts:

Comparing its effectiveness to other immunosuppressive regimens in stem cell transplantation for acute myeloid leukemia^[4]
Evaluating its use in preventing graft-versus-host disease in pediatric patients^[6]
Studying its role in treating steroid-refractory acute graft-versus-host disease^[3]
Investigating its potential in treating autoimmune diseases like systemic sclerosis^[5]

These ongoing studies aim to further refine the use of this important medication and potentially expand its applications in transplant medicine and beyond.

Trial Focus	Patient Population	Key Objectives	Treatment Comparison
Stem cell transplantation in AML/MDS	Adults aged 50-70 with AML or MDS	Compare GVHD prophylaxis efficacy	ATG-thymoglobulin vs ATLG-grafalon
Conditioning for pediatric AML transplants	Children/young adults with AML	Compare conditioning regimens	CloFluBu vs BuCyMel (both including ATG)
Systemic sclerosis treatment	Adults with early diffuse cutaneous systemic sclerosis	Evaluate stem cell transplantation vs. immunosuppression	HSCT (including ATG) vs. conventional immunosuppressants
Kidney transplant rejection prevention	Adult kidney transplant recipients	Compare new drug to standard ATG	Siplizumab vs. rabbit anti-thymocyte globulin (rATG)

Trial Focus

Patient Population

Key Objectives

Treatment Comparison

Stem cell transplantation in AML/MDS

Adults aged 50-70 with AML or MDS

Compare GVHD prophylaxis efficacy

ATG-thymoglobulin vs ATLG-grafalon

Conditioning for pediatric AML transplants

Children/young adults with AML

Compare conditioning regimens

CloFluBu vs BuCyMel (both including ATG)

Systemic sclerosis treatment

Adults with early diffuse cutaneous systemic sclerosis

Evaluate stem cell transplantation vs. immunosuppression

HSCT (including ATG) vs. conventional immunosuppressants

Kidney transplant rejection prevention

Adult kidney transplant recipients

Compare new drug to standard ATG

Siplizumab vs. rabbit anti-thymocyte globulin (rATG)

Ongoing Clinical Trials on Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit

Glossary

Anti-T Lymphocyte Immunoglobulin for Human Use, Rabbit: A medication derived from rabbit antibodies that targets human T lymphocytes (a type of white blood cell). It's used to suppress the immune system in various medical conditions and procedures.
Graft-versus-host disease (GVHD): A complication that can occur after a stem cell or bone marrow transplant where the donor's immune cells attack the recipient's tissues.
Stem cell transplantation: A procedure in which healthy blood-forming stem cells are used to replace damaged or diseased bone marrow. It's often used to treat blood cancers and other blood disorders.
Acute myeloid leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.
Myelodysplastic syndrome (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, which can sometimes progress to acute myeloid leukemia.
Systemic sclerosis: An autoimmune disease characterized by hardening and tightening of the skin and connective tissues, which can also affect internal organs.
Conditioning regimen: A treatment plan, often involving chemotherapy and/or radiation, used to prepare a patient's body for stem cell transplantation.
Immunosuppression: The intentional reduction of the activation or efficacy of the immune system, often used to prevent rejection in organ transplants or to treat autoimmune diseases.
Allogeneic: Referring to cells, tissues, or organs that are transferred from one individual to another of the same species but with different genetic makeup.
HLA matching: The process of finding a donor whose human leukocyte antigens (HLA) are compatible with the recipient's, which is important for reducing the risk of rejection in transplants.

References

http://clinicaltrials.eu/trial/study-comparing-thymoglobulin-and-grafalon-for-preventing-graft-versus-host-disease-in-elderly-patients-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome/
http://clinicaltrials.eu/trial/study-on-siplizumab-and-rabbit-anti-thymocyte-globulin-for-preventing-rejection-in-new-kidney-transplant-patients/
http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-mesenchymal-stromal-cells-in-children-with-steroid-refractory-acute-graft-versus-host-disease/
http://clinicaltrials.eu/trial/study-comparing-clofarabine-busulfan-and-fludarabine-busulfan-for-adults-with-acute-myeloid-leukemia-eligible-for-stem-cell-transplantation/
http://clinicaltrials.eu/trial/study-on-early-diffuse-cutaneous-systemic-sclerosis-comparing-stem-cell-transplantation-with-cyclophosphamide-filgrastim-and-mycophenolate-mofetil/
http://clinicaltrials.eu/trial/study-on-conditioning-treatments-with-busulfan-clofarabine-and-fludarabine-for-children-with-acute-myeloid-leukemia-undergoing-stem-cell-transplantation/

#1 Clinical Trials Search in Europe